Search Results
Mar 31, 2026, 09:00 ET RGNX Shareholder Alert: Investors With Losses May Seek to Lead the Class Action in REGENXBIO Inc. Securities Lawsuit -- The Gross Law Firm
press release announcing that the FDA placed a clinical hold on its investigational gene therapy RGX-111. Defendants announced that an intraventricular CNS tumor was found in a participant treated in its RGX-111 Phase I/II study. Following this news, the price of REGENXBIO's common stock declined from a
More news about: The Gross Law Firm
Mar 31, 2026, 08:05 ET Rigel Announces Publication of Final ARROW Clinical Trial Data on GAVRETO® (pralsetinib) in Patients with RET+ NSCLC in the Journal of Clinical Oncology
months).Fifteen patients had measurable central nervous system (CNS) metastases at baseline. The intracranial response rate (CNS ORR) among these patients was 53%. In the 11 response-evaluable patients with CNS metastases, CNS ORR was 73%.The publication, titled "Final Efficacy and
More news about: Rigel Pharmaceuticals, Inc.
Mar 31, 2026, 06:38 ET 理大開辦獲認證之營養治療理學碩士課程 培育新一代營養人才
理大與業界各機構緊密聯繫，學生可獲得與業界接觸及交流的寶貴機會，提升職涯競爭力。 權威認證及國際專業發展路徑課程已獲中國營養學會（CNS）官方認證，同時，理大亦是 CNS 註冊營養師（RD）在香港的指定培訓基地。畢業生可報考 CNS 註冊營養師（RD）資格，亦可申請註冊成為英國健康與護理專業委員會（The Health and Care Professions Council, HCPC）註冊營養師。了解更多及申請方法2026-27年度營養治療理學碩士課程現正接受報名，申請截止日期為
More news about: 香港理工大學
Mar 31, 2026, 06:30 ET Immunic Strengthens Its Board of Directors with the Appointment of Seasoned Biopharmaceutical Executive Jon Congleton
Board member of both CNS company Impel NeuroPharma, Inc. and cystic fibrosis company Nivalis Therapeutics, Inc.. Earlier, Mr. Congleton held several senior leadership roles at Teva Pharmaceuticals, eventually leading its United States and Canadian neuroscience businesses and global CNS franchise."MS
More news about: Immunic, Inc.
Mar 31, 2026, 04:00 ET Gentronix Now Operating Under the Scantox Brand
high-quality, regulator-ready data while keeping timelines and execution aligned across disciplines.Scantox is recognized for deep expertise in CNS pharmacology and Göttingen minipig research, with advanced genetic toxicology and genomic safety capabilities including Big Blue® transgenic rodent assays
More news about: Scantox Group
Mar 30, 2026, 18:58 ET STASH DISPENSARIES BRINGS ROSINMANIA 26 TO ORLAND HILLS WITH MICRO WRESTLING WARRIORS -- A HIGH-ENERGY LIVE EXPERIENCE
BotanicalsRealeaf BotanicalsFernwayLegacyAscendGrassrootsGalaxyKaviarBreezeCNS/DOCTickets are available now at:
More news about: Stash Dispensaries
Mar 30, 2026, 16:00 ET Cohen & Steers Closed-End Opportunity Fund, Inc. (FOF) Notification of Sources of Distribution Under Section 19(a)
https://www.cohenandsteers.comSymbol: (NYSE: CNS)
More news about: Cohen & Steers, Inc.
Mar 30, 2026, 16:00 ET Cohen & Steers Quality Income Realty Fund, Inc. (RQI) Notification of Sources of Distribution Under Section 19(a)
https://www.cohenandsteers.comSymbol: (NYSE: CNS)
More news about: Cohen & Steers, Inc.
Mar 30, 2026, 16:00 ET Cohen & Steers Infrastructure Fund, Inc. (UTF) Notification of Sources of Distribution Under Section 19(a)
https://www.cohenandsteers.comSymbol: (NYSE: CNS)
More news about: Cohen & Steers, Inc.
Mar 30, 2026, 16:00 ET Cohen & Steers Total Return Realty Fund, Inc. (RFI) Notification of Sources of Distribution Under Section 19(a)
https://www.cohenandsteers.comSymbol: (NYSE: CNS)
More news about: Cohen & Steers, Inc.
Mar 30, 2026, 16:00 ET Cohen & Steers REIT and Preferred and Income Fund, Inc. (RNP) Notification of Sources of Distribution Under Section 19(a)
https://www.cohenandsteers.com/Symbol: (NYSE: CNS)
More news about: Cohen & Steers, Inc.
Mar 30, 2026, 09:53 ET Harbour BioMed Reports Full Year 2025 Financial Results: Sustained Global Collaboration Underpins Long-Term Growth
developability/immunogenicity/pharmacokinetics (PK) assessments, as well as patient biomarker studies.CNS Disease Programs: Resilience Neuroscience, a wholly-owned subsidiary of the Company, is advancing a next-generation central nervous system (CNS) pipeline focused on Alzheimer's disease, Parkinson's disease, and other neurodegenerative
More news about: Harbour BioMed
Mar 30, 2026, 04:02 ET RGNX Investors Have Opportunity to Lead REGENXBIO Inc. Securities Fraud Lawsuit with the Schall Law Firm
candidate RGX-111 were overwhelmingly positive while it concealed negative data on its efficacy and safety. The Company then revealed an intraventricular CNS tumor was discovered in a participant treated as part of a RGX-111 study. Based on these facts, the Company's public statements were false and materially
More news about: The Schall Law Firm
Mar 29, 2026, 08:07 ET RGNX DEADLINE ALERT: Faruqi & Faruqi, LLP Reminds REGENXBIO Investors of Securities Class Action Deadline on April 14, 2026
therapy, RGX-111, for the treatment of MPS I, also known as Hurler syndrome, following preliminary analysis of a single case of neoplasm (intraventricular CNS tumor) in a participant treated in its Phase I/II study." The press release also disclosed that "[t]he FDA also placed a clinical hold on RGX-121, for
More news about: Faruqi & Faruqi, LLP
Mar 27, 2026, 08:00 ET Otsuka Pharmaceutical to Acquire Transcend Therapeutics
receptors (i.e., not hallucinogenic). Transcend is developing TSND-201 as a rapid-acting and durable treatment for PTSD and other central nervous system (CNS) indications. TSND-201 is an investigational medication.About Transcend TherapeuticsTranscend, founded in 2021 and based
More news about: Otsuka Pharmaceutical Co.; Transcend Therapeutics
Mar 26, 2026, 23:54 ET Akeso Reports Full-Year 2025 Financial Results
antibody, AK150, is in clinical development, with more trispecific/multispecific and TCE assets approaching the clinic.Immune and CNS Diseases Enter the Dual-Target EraBeyond building global competitiveness in oncology, Akeso has created a powerful new growth
More news about: Akeso, Inc.
Mar 26, 2026, 16:05 ET Eisai and Nuvation Bio Announce Marketing Authorisation Application for Taletrectinib for the Treatment of Advanced ROS1-Positive Non-Small Cell Lung Cancer Validated by the European Medicines Agency
disease progression, with about 50% of previously treated patients developing central nervous system (CNS) metastases.About TaletrectinibTaletrectinib is an oral, potent, CNS-active, selective, next-generation ROS1 inhibitor therapy. On June 11, 2025, following Priority Review and
More news about: Nuvation Bio Inc.; Eisai Co., Ltd
Mar 26, 2026, 10:08 ET Insilico Medicine and Tenacia Biotechnology Expand AI-Driven CNS Collaboration with Deal Value Up to US$94.75 Million
Insilico has continued to expand its footprint in CNS therapeutics in recent years. In early 2026, Insilico entered into a co-development agreement with Hygtia Therapeutics, a joint venture of Fosun Pharma, [Legal1] to advance ISM8969 targeting NLRP3 for CNS treatment. The parties will share 50/50 global
More news about: Insilico Medicine
Mar 26, 2026, 10:00 ET INVESTOR ALERT: Pomerantz Law Firm Reminds Investors with Losses on their Investment in REGENXBIO Inc. of Class Action Lawsuit and Upcoming Deadlines - RGNX
therapy, RGX-111, for the treatment of MPS I, also known as Hurler syndrome, following preliminary analysis of a single case of neoplasm (intraventricular CNS tumor) in a participant treated in its Phase I/II study." The press release also disclosed that "[t]he FDA also placed a clinical hold on RGX-121, for
More news about: Pomerantz LLP
Mar 26, 2026, 09:00 ET SUEWALLST, LLP: INSTITUTIONAL RGNX HOLDERS FACE PORTFOLIO LOSSES FROM GENE THERAPY FRAUD
single trading session on January 28, 2026, after the FDA placed a clinical hold on the Company's RGX-111 gene therapy program following discovery of a CNS tumor in a trial participant. The Court has set April 14, 2026 as the deadline to apply for lead plaintiff appointment.Notice to Institutional
More news about: SueWallSt.com
Mar 26, 2026, 08:50 ET Lunai Bioworks Executes $20M Strategic Transaction at Fixed $1.50 Conversion, Acquiring BBB Delivery Platform for CNS Alzheimer's Therapies with Broad CNS Delivery Applications
is that it directly strengthens Lunai's CNS Alzheimer's pipeline by pairing precise biological target identification with a proven delivery method. At the same time, it expands the Company's ability to develop next-generation treatments across a broad range of CNS disorders where traditional drugs struggle
More news about: Lunai Bioworks Inc.
Mar 26, 2026, 08:00 ET Pulmatrix and Eos SENOLYTIX Announce Merger Agreement to Advance Novel Mitochondrial Therapies to Improve Healthspan
unmet medical needs using its patented iSPERSE™ technology. The Company's proprietary product pipeline includes treatments for central nervous system ("CNS") disorders such as acute migraine and serious lung diseases such as Chronic Obstructive Pulmonary Disease ("COPD") and allergic bronchopulmonary aspergillosis
More news about: Pulmatrix Inc.
Mar 25, 2026, 09:00 ET STEPHEN PAKOLA OVERSAW RGX-111 SAFETY CLAIMS THAT COST RGNX INVESTORS MILLIONS: LEVI & KORSINSKY, LLP
made a series of statements emphasizing that RGX-111 was "well-tolerated" with "no drug-related serious adverse events" and highlighting "encouraging CNS biomarker activity." These statements spanned multiple disclosure events:February 9, 2022: Announced "no drug-related serious
More news about: Levi & Korsinsky, LLP
Mar 25, 2026, 03:24 ET Peptide Therapeutics Market Growing at 7.16% CAGR to Reach USD 70.20 Bn by 2031 Driven by Rising Cancer Prevalence & Metabolic Disorder Burden, Reports Mordor Intelligence
Oncology Metabolic Disorders Cardiovascular Disorders Infectious Diseases Gastrointestinal Disorders CNS Disorders By Route of Administration Parenteral Oral Pulmonary & Nasal Transdermal
More news about: Mordor Intelligence Private Limited
Mar 24, 2026, 17:06 ET Cohen & Steers Closed-End Funds Declare Distributions for April, May and June 2026
https://www.cohenandsteers.com/Symbol: (NYSE: CNS)
More news about: Cohen & Steers, Inc.